NO20002613D0 - Vaksiner med en LTB-adjuvant - Google Patents

Vaksiner med en LTB-adjuvant

Info

Publication number
NO20002613D0
NO20002613D0 NO20002613A NO20002613A NO20002613D0 NO 20002613 D0 NO20002613 D0 NO 20002613D0 NO 20002613 A NO20002613 A NO 20002613A NO 20002613 A NO20002613 A NO 20002613A NO 20002613 D0 NO20002613 D0 NO 20002613D0
Authority
NO
Norway
Prior art keywords
vaccines
immunogen
vaccine
ltb
adjuvant
Prior art date
Application number
NO20002613A
Other languages
English (en)
Other versions
NO324690B1 (no
NO20002613L (no
Inventor
Etienne Agsteribbe
Rudi Brands
Lolke De Haan
Gustaaf Johan Mar Scharrenburg
Willem Ronald Verweij
Jan Christiaan Wilschut
Original Assignee
Duphar Int Res
Universiteit Van Groningen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duphar Int Res, Universiteit Van Groningen filed Critical Duphar Int Res
Publication of NO20002613D0 publication Critical patent/NO20002613D0/no
Publication of NO20002613L publication Critical patent/NO20002613L/no
Publication of NO324690B1 publication Critical patent/NO324690B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
NO20002613A 1997-11-25 2000-05-22 Vaksine inneholdende en LTB-adjuvant samt anvendelse av nevnte vaksine NO324690B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP97203671A EP0919243A1 (en) 1997-11-25 1997-11-25 Vaccine containing B subunits of heat-labile enterotoxin (LTB) of Escherichia coli as an adjuvant
PCT/EP1998/007553 WO1999026654A1 (en) 1997-11-25 1998-11-24 Vaccines with an ltb adjuvant

Publications (3)

Publication Number Publication Date
NO20002613D0 true NO20002613D0 (no) 2000-05-22
NO20002613L NO20002613L (no) 2000-05-22
NO324690B1 NO324690B1 (no) 2007-12-03

Family

ID=8228966

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20002613A NO324690B1 (no) 1997-11-25 2000-05-22 Vaksine inneholdende en LTB-adjuvant samt anvendelse av nevnte vaksine

Country Status (25)

Country Link
US (1) US6793928B1 (no)
EP (2) EP0919243A1 (no)
JP (1) JP4235359B2 (no)
KR (1) KR100575019B1 (no)
CN (1) CN1227032C (no)
AT (1) ATE238809T1 (no)
AU (1) AU747061C (no)
BR (1) BR9815413A (no)
CA (1) CA2311492C (no)
CZ (1) CZ299770B6 (no)
DE (1) DE69814177T2 (no)
DK (1) DK1071456T3 (no)
ES (1) ES2198089T3 (no)
HK (1) HK1031102A1 (no)
HU (1) HU226214B1 (no)
IL (2) IL135905A0 (no)
NO (1) NO324690B1 (no)
NZ (1) NZ504396A (no)
PL (1) PL190925B1 (no)
PT (1) PT1071456E (no)
RU (1) RU2211050C2 (no)
SK (1) SK284572B6 (no)
TR (1) TR200001485T2 (no)
UA (1) UA72199C2 (no)
WO (1) WO1999026654A1 (no)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9326174D0 (en) * 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
AU2003261492B2 (en) * 1998-05-08 2006-09-07 Trident Pharmaceuticals, Inc. Vaccine
US7914791B1 (en) 1998-05-08 2011-03-29 Trident Pharmaceuticals, Inc. Vaccine
NZ507911A (en) * 1998-05-08 2004-04-30 Univ Bristol Immunomodulators for vaccines
CA2388054C (en) * 1999-10-18 2012-12-11 Chiron Corporation Compositions and methods for stimulating an immune response against infectious agents
IL158140A0 (en) * 2003-09-25 2004-03-28 Hadasit Med Res Service Multiepitope polypeptides for cancer immunotherapy
EP1708744A4 (en) * 2003-12-09 2009-07-15 Intercell Usa Inc GM1 Binding Dereficent Exotoxins for Use as Immunoinguarantees
EP1930025B1 (en) 2005-08-05 2013-05-01 The University of Tokushima ANTIGEN-AND-DRUG VEHICLE WHICH ENABLES THE CHANGEOVER FROM THE SELECTIVE PRODUCTION OF IgA ANTIBODY TO THE PRODUCTION OF BOTH OF IgA AND IgG ANTIBODIES, AND TRANSNASAL/TRANSMUCOSAL VACCINE USING THE VEHICLE
TWI397419B (zh) * 2006-03-22 2013-06-01 Abbott Biologicals Bv 病毒顆粒的鼻內或吸入給藥
US8652782B2 (en) 2006-09-12 2014-02-18 Longhorn Vaccines & Diagnostics, Llc Compositions and methods for detecting, identifying and quantitating mycobacterial-specific nucleic acids
US8097419B2 (en) 2006-09-12 2012-01-17 Longhorn Vaccines & Diagnostics Llc Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009
US8080645B2 (en) 2007-10-01 2011-12-20 Longhorn Vaccines & Diagnostics Llc Biological specimen collection/transport compositions and methods
US9598462B2 (en) 2012-01-26 2017-03-21 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
US9481912B2 (en) 2006-09-12 2016-11-01 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and identifying nucleic acid sequences in biological samples
ES2376010T3 (es) 2006-10-12 2012-03-08 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.R.L. Prote�?na de fusión de transcriptasa inversa de la telomerasa, nucleótidos que la codifican y usos de la misma.
US11041215B2 (en) 2007-08-24 2021-06-22 Longhorn Vaccines And Diagnostics, Llc PCR ready compositions and methods for detecting and identifying nucleic acid sequences
US9683256B2 (en) 2007-10-01 2017-06-20 Longhorn Vaccines And Diagnostics, Llc Biological specimen collection and transport system
US10004799B2 (en) 2007-08-27 2018-06-26 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
EP2772267B1 (en) 2007-08-27 2016-04-27 Longhorn Vaccines and Diagnostics, LLC Immunogenic compositions and methods
CA2861667C (en) 2007-10-01 2017-06-13 Longhorn Vaccines And Diagnostics, Llc Biological specimen collection and transport system and methods of use
US11041216B2 (en) 2007-10-01 2021-06-22 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples
KR101887040B1 (ko) * 2012-06-20 2018-08-09 고쿠리츠다이가쿠호징 도쿄다이가쿠 점막 면역 부활화제 및 hpv 감염증 치료용 경구 의약 조성물
CN106170551B (zh) 2013-12-16 2020-01-07 财团法人农业科技研究院 生产不耐热肠毒素b亚单位的质粒、方法及其套组
CA2985652C (en) 2015-05-14 2020-03-10 Gerald W. FISHER Rapid methods for the extraction of nucleic acids from biological samples
KR20200083540A (ko) * 2017-11-01 2020-07-08 머크 샤프 앤드 돔 코포레이션 시토메갈로바이러스의 안정한 제형
EP3737750A4 (en) 2018-01-09 2021-11-17 Synthetic Biologics, Inc. ALKALINE PHOSPHATASE AGENTS FOR THE TREATMENT OF NEURODevelopmental Disorders
US11638699B2 (en) 2018-03-20 2023-05-02 Theriva Biologics, Inc. Intestinal alkaline phosphatase formulations
US11654184B2 (en) 2018-03-20 2023-05-23 Theriva Biologics, Inc. Alkaline phosphatase agents for treatment of radiation disorders
TWI811673B (zh) * 2020-05-08 2023-08-11 昱厚生技股份有限公司 使用免疫調節劑及包含其之疫苗組合物預防或治療冠狀病毒感染之方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH589453A5 (no) 1974-01-14 1977-07-15 Sandoz Ag
JP2849632B2 (ja) * 1988-04-08 1999-01-20 社団法人北里研究所 ワクチン製剤
AU4754490A (en) * 1988-12-07 1990-06-26 University Of Leicester Heat-labile toxin b subunit fusion proteins
US5241053A (en) * 1990-09-05 1993-08-31 Takeda Chemical Industries, Ltd. Fused proteins comprising glycoprotein gD of HSV-1 and LTB

Also Published As

Publication number Publication date
KR20010032425A (ko) 2001-04-16
HUP0100058A1 (hu) 2001-05-28
HUP0100058A3 (en) 2003-03-28
CN1280504A (zh) 2001-01-17
BR9815413A (pt) 2000-10-17
IL135905A0 (en) 2001-05-20
ATE238809T1 (de) 2003-05-15
PL340635A1 (en) 2001-02-12
ES2198089T3 (es) 2004-01-16
AU1875099A (en) 1999-06-15
WO1999026654A1 (en) 1999-06-03
JP2001523729A (ja) 2001-11-27
NO324690B1 (no) 2007-12-03
CA2311492A1 (en) 1999-06-03
PT1071456E (pt) 2003-09-30
AU747061C (en) 2005-02-24
EP0919243A1 (en) 1999-06-02
AU747061B2 (en) 2002-05-09
TR200001485T2 (tr) 2001-12-21
JP4235359B2 (ja) 2009-03-11
PL190925B1 (pl) 2006-02-28
SK7762000A3 (en) 2000-11-07
US6793928B1 (en) 2004-09-21
EP1071456B1 (en) 2003-05-02
CA2311492C (en) 2011-10-18
KR100575019B1 (ko) 2006-05-02
RU2211050C2 (ru) 2003-08-27
CZ20001895A3 (cs) 2000-10-11
HK1031102A1 (en) 2001-06-01
CZ299770B6 (cs) 2008-11-19
UA72199C2 (en) 2005-02-15
NO20002613L (no) 2000-05-22
DE69814177T2 (de) 2004-04-08
DK1071456T3 (da) 2003-06-02
HU226214B1 (en) 2008-06-30
EP1071456A1 (en) 2001-01-31
IL135905A (en) 2006-08-01
NZ504396A (en) 2002-09-27
CN1227032C (zh) 2005-11-16
DE69814177D1 (de) 2003-06-05
SK284572B6 (sk) 2005-06-02

Similar Documents

Publication Publication Date Title
DK1071456T3 (da) Vacciner med en LTB-adjuvant
DE60012711D1 (de) Adjuvanszusammensetzungen zur erhöhung der immunantwort auf polynukleotid-basierende impfstoffe
CY1108272T1 (el) Αδρανοποιημενο εμβολιο ιου γριππης για ρινικη ή στοματικη χορηγηση
BR9305711A (pt) Vacina à base de urease contra infecção por helicobacter
HUP9901901A2 (hu) Hepatitis C elleni vakcinák
BR0007936A (pt) Composto, formulação adjuvante imunológica, formulação de vacina, e, processo para estimular uma resposta imune a um antìgeno
MX9702336A (es) Composiciones de vacuna.
DE69333028D1 (de) Deletionsmutanten als impfstoffe gegen cholera
WO1999065518A3 (en) Lt and ct in parenteral immunization methods against helicobacter infection
ATE392429T1 (de) Lebend-impfstoff gegen heliobacter pylori
WO2001035993A3 (en) Compositions and methods for stimulating an immune response against infectious agents
WO2000074630A3 (en) Dna vaccine for protecting an avian against infectious bursal disease virus
DK0729509T3 (da) Vaccine imod fåresyge indeholdende en Jeryl-Lynn virus-stamme
ATE195427T1 (de) Pertussistoxin enthaltender influenzaimpfstoff

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: ABBOTT BIOLOGICALS BV, NL

MM1K Lapsed by not paying the annual fees